Substituted oxazines as beta-secretase inhibitors

US10947223B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Jennifer R. Allen · Newbury Park, US
• Matthew P. Bourbeau · Calabasas, US
• Ning Chen · Thousand Oaks, US
• Michael J. Frohn · Thousand Oaks, US
• Paul E. Harrington · Camarillo, US
• Qingyian Liu · Camarillo, US
• Corey REEVES · West Hollywood, US

Key dates

• Filing date: Dec 13, 2017
• Grant date: Mar 16, 2021
• Expiry date: Dec 13, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: (insert Formula I structure) wherein variables W, X, Y, R2, R2′, R3, R4, R5, R6, and R7 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to beta amyloid (Aβ) plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.